Importantly, because ARG1 and not ARG2 is the main hepatic ureagenic enzyme in mammals17–21, specific targeting of ARG2 may provide a therapeutic opportunity for the treatment of pancreatic cancer patients, particularly those suffering from obesity and the metabolic syndrome. Here, ARG1 is linked to pancreatic neoplasm.